|
Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - ESSA |
Travel, Accommodations, Expenses - ESSA |
|
|
Consulting or Advisory Role - ESSA |
|
|
|
Stock and Other Ownership Interests - ESSA |
|
|
|
Stock and Other Ownership Interests - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
|
Stock and Other Ownership Interests - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
|
Leadership - Arch Oncology; Refuge Biotech |
Stock and Other Ownership Interests - ESSA |